April 28, 2022
Daiichi Sankyo saw its group revenue reach 1 trillion yen in FY2021 as global sales of its cancer drug Enhertu (trastuzumab deruxtecan) more than doubled from the prior year and its top-selling product Lixiana (edoxaban) expanded market shares. In the...read more